Printer Friendly

BAYER TO MARKET SYNTRO VACCINE IN EUROPE

 BAYER TO MARKET SYNTRO VACCINE IN EUROPE
 KANSAS CITY, Mo., July 30 /PRNewswire/ -- Syntro Corporation


(NASDAQ-NMS: SYNT) today announced that Bayer AG will market and distribute Syntro's PRV/Marker Gold(R) genetically designed vaccines in Europe, following necessary regulatory approvals. Under terms of the agreement, the vaccines will be supplied by SyntroVet Incorporated, a wholly owned subsidiary of Syntro.
 PRV/Marker Gold vaccines prevent pseudorabies, a serious infectious disease of swine caused by a herpesvirus. Known also as "Aujeszky's Disease," pseudorabies causes major economic losses to the swine industry and is the target of eradication efforts in both the United States and Europe.
 Eradication programs require vaccines that effectively stop the spread of infection while allowing the detection of disease carriers by the use of special antibody tests. PRV/Marker Gold was genetically designed by Syntro scientists to meet these criteria, and has captured a major share of the pseudorabies vaccine market in the United States.
 Headquartered in Germany, Bayer AG is an international, broadly diversified chemical and health care company with operations in some 150 countries. The company holds a leading position in the animal health market in Germany and is among the market leaders in most other important animal health markets. In 1991, Bayer reported group sales of approximately 42 billion DM ($28 billion).
 Syntro Corporation is a Kansas City and San Diego-based biotechnology company engaged in the development and commercialization of genetically engineered vaccines for the animal health market. SyntroVet Incorporated manufactures and markets products resulting from Syntro's research programs.
 -0- 7/30/92
 /CONTACT: Jack Falker of Swenson Falker Eilertsen, 612-371-0000, for Syntro, or Dr. J. Donald Todd of Syntro, 913-888-8876/
 (SYNT) CO: Syntro Corporation ST: Missouri IN: SU:


AL -- MN004 -- 4872 07/30/92 07:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 30, 1992
Words:292
Previous Article:DURACELL REPORTS RECORD RESULTS FOR ITS FOURTH QUARTER AND FULL FISCAL YEAR
Next Article:HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
Topics:


Related Articles
SYNTRO REPORTS FOURTH QUARTER PROFIT AND IMPROVED OPERATING RESULTS FOR FISCAL 1991
SYNTRO AND HOECHST TO DEVELOP VACCINES
HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
SYNTRO ANNOUNCES APPROVAL OF SWINE FLU VACCINE
SYNTRO VIRAL VECTOR VACCINE APPROVED FOR FINAL TESTING
SYNTRO AND SUBSIDIARY NAMED IN COMPLAINT
SYNTRO REPORTS SECOND QUARTER RESULTS
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters